Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 2/20 | 0.62 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16350132 | 1.00 | CPA3 (0.62) | CPA3ITGA4ITGB7CYP1A2FOLH1 | |
| SCHEMBL27471452 | 0.88 | CPA3 (0.51) | CPA3ITGA4ITGB7CYP1A2CPA1 | |
| SCHEMBL20168730 | 0.86 | CPA3 (0.46) | CPA3FOLH1 | |
| SCHEMBL1519540 | 0.85 | CPA3 (0.44) | CPA3 | |
| SCHEMBL1519542 | 0.85 | CPA3 (0.44) | CPA3 | |
| SCHEMBL1519833 | 0.85 | CPA1 (0.60) | CPA3ITGA4ITGB7CYP1A2CPA1 | |
| SCHEMBL1916688 | 0.85 | CPA1 (0.60) | CPA3ITGA4ITGB7CYP1A2CPA1 | |
| SCHEMBL1519838 | 0.85 | CPA1 (0.60) | CPA3ITGA4ITGB7CYP1A2CPA1 | |
| SCHEMBL20168326 | 0.85 | SLC7A5 (0.61) | CPA3FOLH1 | |
| Water SCHEMBL28198514 | 0.84 | ITGA4 (0.45) | CPA3ITGA4ITGB7CYP1A2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138145-B2 | Hybrid oligomers, their preparation process and pharmaceutical compositions containing them | Centre National de la Recherche Scientifique (SNRS) (FR) | 2012-03-20 | — | — | US | disclosed |
| US-20100298206-A1 | HYBRID OLIGOMERS, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), I.B.M.C. (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298206-A1 | HYBRID OLIGOMERS, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOD2, NOD1, COG5 | CPA3 3506/4885ITGA4 3392/4885ITGB7 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.